Cargando…

Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C

The advent of direct-acting antiviral drugs (DAAs) was a breakthrough in the treatment of patients with chronic hepatitis C, yet high viral replication errors can lead to the development of resistance associated variants (RAVs). Thus, assessment of RAV in infected patients is necessary to monitor tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Valutite, Diana, Ostankova, Yulia, Semenov, Alexandr, Lyalina, Liudmila, Totolian, Areg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139387/
https://www.ncbi.nlm.nih.gov/pubmed/35626210
http://dx.doi.org/10.3390/diagnostics12051054
_version_ 1784714847827525632
author Valutite, Diana
Ostankova, Yulia
Semenov, Alexandr
Lyalina, Liudmila
Totolian, Areg
author_facet Valutite, Diana
Ostankova, Yulia
Semenov, Alexandr
Lyalina, Liudmila
Totolian, Areg
author_sort Valutite, Diana
collection PubMed
description The advent of direct-acting antiviral drugs (DAAs) was a breakthrough in the treatment of patients with chronic hepatitis C, yet high viral replication errors can lead to the development of resistance associated variants (RAVs). Thus, assessment of RAV in infected patients is necessary to monitor treatment effectiveness. The aim of our study was to investigate the presence of primary resistance mutations in the NS3 and NS5 regions of HCV in treatment-naive patients. Samples were taken from 42 patients with HCV who had not previously received DAA treatment. In the present study, we used the method for determining drug resistance mutations based on direct sequencing of the NS3, NS5A, and NS5B genes developed by the Saint Petersburg Pasteur Institute. Primary mutations associated with resistance were detected in 5 patients (12%). According to the Geno2pheno [hcv] 0.92 database, nucleotide substitutions were identified in various viral genes conferring resistance or decreased sensitivity to the respective inhibitors. This study has shown different mutations in the analyzed genes in patients with HCV who had not previously received DAA treatment. These mutations may increase the likelihood of treatment failure in the future.
format Online
Article
Text
id pubmed-9139387
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91393872022-05-28 Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C Valutite, Diana Ostankova, Yulia Semenov, Alexandr Lyalina, Liudmila Totolian, Areg Diagnostics (Basel) Article The advent of direct-acting antiviral drugs (DAAs) was a breakthrough in the treatment of patients with chronic hepatitis C, yet high viral replication errors can lead to the development of resistance associated variants (RAVs). Thus, assessment of RAV in infected patients is necessary to monitor treatment effectiveness. The aim of our study was to investigate the presence of primary resistance mutations in the NS3 and NS5 regions of HCV in treatment-naive patients. Samples were taken from 42 patients with HCV who had not previously received DAA treatment. In the present study, we used the method for determining drug resistance mutations based on direct sequencing of the NS3, NS5A, and NS5B genes developed by the Saint Petersburg Pasteur Institute. Primary mutations associated with resistance were detected in 5 patients (12%). According to the Geno2pheno [hcv] 0.92 database, nucleotide substitutions were identified in various viral genes conferring resistance or decreased sensitivity to the respective inhibitors. This study has shown different mutations in the analyzed genes in patients with HCV who had not previously received DAA treatment. These mutations may increase the likelihood of treatment failure in the future. MDPI 2022-04-22 /pmc/articles/PMC9139387/ /pubmed/35626210 http://dx.doi.org/10.3390/diagnostics12051054 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Valutite, Diana
Ostankova, Yulia
Semenov, Alexandr
Lyalina, Liudmila
Totolian, Areg
Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C
title Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C
title_full Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C
title_fullStr Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C
title_full_unstemmed Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C
title_short Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C
title_sort distribution of primary resistance mutations in saint petersburg in patients with chronic hepatitis c
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139387/
https://www.ncbi.nlm.nih.gov/pubmed/35626210
http://dx.doi.org/10.3390/diagnostics12051054
work_keys_str_mv AT valutitediana distributionofprimaryresistancemutationsinsaintpetersburginpatientswithchronichepatitisc
AT ostankovayulia distributionofprimaryresistancemutationsinsaintpetersburginpatientswithchronichepatitisc
AT semenovalexandr distributionofprimaryresistancemutationsinsaintpetersburginpatientswithchronichepatitisc
AT lyalinaliudmila distributionofprimaryresistancemutationsinsaintpetersburginpatientswithchronichepatitisc
AT totolianareg distributionofprimaryresistancemutationsinsaintpetersburginpatientswithchronichepatitisc